Veracyte | VCYT - Sales Revenues

Stock Price
32.67
Daily Change
0.52 1.62%
Monthly
-2.10%
Yearly
0.15%
Q2 Forecast
31.28

Veracyte reported $140.6M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
Agenus USD 34.2M 3.97M Dec/2025
Agilent USD 1.8B 63M Dec/2025
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Bruker USD 977.2M 116.7M Dec/2025
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Illumina USD 1.16B 80M Dec/2025
Intrexon USD 717K 511K Jun/2024
Karyopharm Therapeutics USD 34.08M 3.54M Dec/2025
Laboratory Of America USD 3.52B 40M Dec/2025
Ligand Pharmaceuticals USD 59.66M 55.8M Dec/2025
Myriad Genetics USD 209.8M 4.1M Dec/2025
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Siemens EUR 19.14B 2.29B Dec/2025
Sonic Healthcare AUD 5.45B 470M Dec/2025
Thermo Fisher Scientific USD 12.21B 1.09B Dec/2025
Veracyte USD 140.6M 8.7M Dec/2025
Waters USD 932M 132M Dec/2025